TY - JOUR
T1 - Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
AU - Fianchi, Luana
AU - Pagano, Livio
AU - Leoni, Franco
AU - Storti, Sergio
AU - Voso, Maria Teresa
AU - Valentini, Caterina Giovanna
AU - Rutella, Sergio
AU - Caira, Morena
AU - Gianfaldoni, Giacomo
AU - Leone, Giuseppe
PY - 2008
Y1 - 2008
N2 - Background: Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of acute myeloid leukemia
(AML). We evaluated efficacy and safety of a chemotherapy including growth factors, cytarabine, and GO (G-AraMy) in
the treatment of poor-prognosis AML in elderly patients.
Patients and methods: In three Italian hematology departments from September 2003 to September 2006, 53
elderly patients [median age 69 years (range 65–77)] with untreated or primary refractory/relapsed AML were enrolled
on the combination G-AraMy administered according to two consecutive schedules (G-AraMy1 and G-AraMy2), with
intensified consolidation in the second. Twenty-three of 53 patients had a secondary acute myeloid leukemia (sAML).
Results: The overall response rate was 57%. The most common adverse event was myelosuppression. Seven
patients died in induction (13%). No differences for response rate and toxicity profile were observed between untreated
and primary resistant/relapsed patients, de novo AML and sAML, and in the two treatment trials. Median disease-free
survival and overall survival were 8 months (range 2–23+) and 9 months (range 2–24+).
Conclusions: G-AraMy therapy may be considered an useful treatment approach for poor-risk elderly AML patients,
with a complete remission rate comparable to literature data with reduced side-effects, also in a poor-prognosis
AB - Background: Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of acute myeloid leukemia
(AML). We evaluated efficacy and safety of a chemotherapy including growth factors, cytarabine, and GO (G-AraMy) in
the treatment of poor-prognosis AML in elderly patients.
Patients and methods: In three Italian hematology departments from September 2003 to September 2006, 53
elderly patients [median age 69 years (range 65–77)] with untreated or primary refractory/relapsed AML were enrolled
on the combination G-AraMy administered according to two consecutive schedules (G-AraMy1 and G-AraMy2), with
intensified consolidation in the second. Twenty-three of 53 patients had a secondary acute myeloid leukemia (sAML).
Results: The overall response rate was 57%. The most common adverse event was myelosuppression. Seven
patients died in induction (13%). No differences for response rate and toxicity profile were observed between untreated
and primary resistant/relapsed patients, de novo AML and sAML, and in the two treatment trials. Median disease-free
survival and overall survival were 8 months (range 2–23+) and 9 months (range 2–24+).
Conclusions: G-AraMy therapy may be considered an useful treatment approach for poor-risk elderly AML patients,
with a complete remission rate comparable to literature data with reduced side-effects, also in a poor-prognosis
KW - acute mieloyd leukemia
KW - elderly patients
KW - gemtuzumab ozogamicin
KW - acute mieloyd leukemia
KW - elderly patients
KW - gemtuzumab ozogamicin
UR - http://hdl.handle.net/10807/3835
M3 - Article
SN - 0923-7534
SP - 128
EP - 134
JO - Annals of Oncology
JF - Annals of Oncology
ER -